ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1828

SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling

Christopher Wasson1, Stefano Di Donato2, Rebecca Ross3, Vishal Kakkar4 and Francesco Del Galdo1, 1University of Leeds, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 3Medicine and Health, University of Leeds, Leeds, United Kingdom, 4LIRMM University of Leeds, Leeds, United Kingdom

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, interferon, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic Sclerosis is an autoimmune disease which is characterized by fibrosis of the skin and the internal organs with variable severity. Type I interferon signalling plays a major role in disease progression. The cytokine TGF-β has been extensively shown to be a major driver of fibrosis but its role in the context of Type 1 interferon activation is poorly understood. Here we aimed to dissect the crosstalk of TGF-β and type 1 interferon signalling pathways in keratinocytes, monocytes and dermal fibroblasts in SSc.

Methods: Conditioned media from healthy or SSc dermal fibroblasts was collected and used to stimulate the keratinocyte cell line Hacats and the monocyte cell line Thp1. Type 1 interferon responses were measured by analysing phosphorylated STAT1 levels by western blot, ISG expression (ISG15, CXCL10, CXCL11, IFIT1) by RT-qPCR and Interferon responsive luciferase reporter assay. Cells were stimulated with TGF-b (10ng/ml) and the TGFbR1 receptor was inhibited with SD208 (1μM). CLIC4 was disrupted with specific siRNA and the chloride channel inhibitors NPPB and IAA-94. Skin biopsies from wildtype and type 1 interferon receptor KO mice were stimulated with TGF-β ex-vivo.

Results: TGF-β stimulation of Hacats and Thp-1 led to a significant type I interferon activation signature in both cell lines (CXCL10 100-fold, IFIT1 3-fold, ISG15 12-fold). Accordingly TGF-β induced ISG expression in WT mouse skin biopsies ex-vivo and this was attenuated in the type I interferon receptor KO (CXCL11 90% knockdown, IFIT1 80% knockdown, ISG15 90% knockdown). Conditioned media from SSc fibroblasts induced type I interferon signalling in both Hacats and Thp-1 cells and this was nullified when the cells were co-treated with the TGFβR1 inhibitor SD208. Further analysis revealed the chloride channel CLIC4 played an important role in regulating the type 1 interferon response in the keratinocytes by enhancing the TGF-β signalling pathway in the cells. The conditioned media from SSc fibroblasts was unable to induce a type I interferon response in the keratinocytes when CLIC4 was disrupted in the keratinocytes by siRNA or small molecule inhibitors.

Conclusion: This study provides a first set of evidence indicating interplay between TGF-β and the type I interferon signalling pathways in the context of SSc. The cross-talk between the pathways supports the rationale of developing combination strategies for arresting the pathogenic process in SSc.


Disclosures: C. Wasson: None; S. Di Donato: None; R. Ross: Deepcure, 5; V. Kakkar: None; F. Del Galdo: AbbVie, 2, 5, Argenx, 2, Arxx, 2, 5, AstraZeneca, 2, 5, Boehringer Ingelheim, 2, 5, Chemomab, 5, Deepcure, 2, GlaxoSmithKline (GSK), 2, Janssen, 2, Mitsubishi Tanabe, 5, Novartis, 2, Ventus, 2.

To cite this abstract in AMA style:

Wasson C, Di Donato S, Ross R, Kakkar V, Del Galdo F. SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/ssc-fibroblasts-trigger-a-systemic-type-i-interferon-response-in-ssc-patients-through-canonical-tgf-%ce%b2-receptor-signalling/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ssc-fibroblasts-trigger-a-systemic-type-i-interferon-response-in-ssc-patients-through-canonical-tgf-%ce%b2-receptor-signalling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology